Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

Who is this study for? Patients with idiopathic pulmonary fibrosis
What treatments are being studied? PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 85
Healthy Volunteers: f
View:

• Age between 40-85 years old.

• A diagnosis of IPF that fulfills American Thoracic Society (ATS) / European Respiratory Society (ERS) 2018 consensus criteria within 5 years.

• Ability and willingness to give informed consent and adhere to study requirements.

• Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) \>0.70.

• High or mixed affinity binder for TSPO ligands based on genotyping for single-nucleotide polymorphism (SNP)rs6971.

Locations
United States
Alabama
The University of Alabama at Birmingham
RECRUITING
Birmingham
Contact Information
Primary
Jonathan McConathy, MD, PhD
jmcconathy@uabmc.edu
205-996-7115
Backup
April Riddle, BSRT
ariddle@uabmc.edu
205-934-6504
Time Frame
Start Date: 2020-12-08
Estimated Completion Date: 2027-06
Participants
Target number of participants: 10
Treatments
Experimental: PET/CT using PET ligands [18F]FDG and [18F]DPA-714
Sponsors
Leads: University of Alabama at Birmingham

This content was sourced from clinicaltrials.gov